European Commission approves Rezurock (belumosudil) to treat chronic graft-vs-host disease – Sanofi
The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years… read more.
